FibroGen Inc. has announced the entry into a Third Amendment to its existing financing agreement with investment funds managed by Morgan Stanley Tactical Value. The amendment, dated July 14, 2025, involves a reduction in the minimum qualified cash balance that FibroGen is required to maintain in its U.S. deposit or securities accounts, lowering the amount from $22.5 million to $18.75 million. This amendment is part of an ongoing financing arrangement initially established on April 29, 2023, and managed by Wilmington Trust National Association as the administrative agent. The details of this amendment are documented in the full text filed as Exhibit 10.1 to the company's current report on Form 8-K.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。